Starpharma Holdings Limited announced that VIRALEZETM antiviral nasal spray has been registered for sale in Saudi Arabia. This is the first registration for VIRALEZETM in the Middle East and registration in Saudi Arabia is an important step for other countries in the region. Saudi Arabia has a population of approx. 35 million and contributes almost half of the annual GDP in the GCC (Gulf Cooperation Council) region. Starpharma is well advanced in negotiations for distribution of VIRALEZETM in Saudi Arabia. In the meantime, consumers in Saudi Arabia can purchase VIRALEZETM online. VIRALEZETM is a broad-spectrum antiviral nasal spray that contains SPL7013, which has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses, including inactivation of >99.9% of the Delta variant of SARS-CoV-2, in laboratory studies Antiviral laboratory testing of SPL7013 earlier this year also confirmed it is active in other respiratory viruses, including influenza as well as two other pandemic coronaviruses – Middle East respiratory syndrome coronavirus (MERSCoV) or "MERS" and severe acute respiratory syndrome (SARS-CoV) or "SARS". There are no vaccines available for MERS or SARS.